BMRN Stock Cash Flow Statements

BioMarin Pharmaceutical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

BioMarin Pharmaceutical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2013-12-31	2013-09-30	2012-12-31	2012-09-30	2011-12-31	2011-09-30	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31

cash flows from operating activities:
net income	240,532,000	185,686,000	124,943,000	106,080,000	107,174,000	88,662,000	20,375,000	40,378,000	56,040,000	50,852,000	-249,000	-6,652,000	27,664,000	120,798,000	-57,898,000	-36,494,000	12,941,000	17,371,000	22,099,000	784,803,000	-29,183,000	81,381,000	15,024,000	55,036,000	-37,435,000	-56,473,000	-61,990,000	-53,020,000	-53,012,000	-5,357,000	-26,735,000	-17,653,000	-12,189,000	217,334,000	-477,000	1,151,000	4,711,000	6,641,000	1,312,000	-13,152,000	24,506,000	829,000	3,810,000	1,686,000	2,570,000	-5,216,000	-3,864,000	-9,293,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	18,563,000	22,069,000	23,607,000	19,006,000	26,463,000	27,350,000	26,861,000	25,685,000	25,419,000	26,421,000	24,553,000	24,802,000	25,271,000	27,343,000	25,986,000	26,839,000	27,231,000	27,983,000	27,358,000	26,634,000	25,216,000	25,964,000	25,790,000	30,739,000	26,344,000	22,427,000	9,384,000	13,375,000	11,857,000	11,667,000	9,628,000	9,350,000	7,931,000	7,819,000	6,577,000	5,410,000	4,861,000	4,841,000	6,170,000	5,103,000	4,757,000	4,554,000	4,450,000	3,870,000	3,705,000	3,489,000	3,313,000	3,036,000
non-cash interest expense	660,000	660,000	660,000	718,000	991,000	990,000	990,000	1,140,000	1,029,000	1,029,000	1,028,000	1,027,000	1,029,000	1,033,000	1,032,000	1,032,000	1,039,000	1,043,000	1,745,000	5,232,000	4,916,000	4,618,000	4,565,000	525,000	4,461,000	4,409,000
accretion of discount on investments	-1,355,000	-1,362,000		-1,941,000	-2,176,000	-2,502,000																			-619,000	-891,000	1,631,000	1,320,000
stock-based compensation	47,531,000	37,700,000	51,919,000	43,489,000	47,914,000	58,249,000	54,855,000	48,387,000	50,162,000	53,695,000	46,734,000	54,663,000	47,078,000	47,833,000		49,026,000	54,843,000	49,503,000		50,169,000	44,962,000	46,994,000		39,173,000	39,829,000	42,761,000	23,543,000	16,790,000	11,926,000	11,990,000	11,188,000	11,784,000	9,835,000	10,294,000	9,627,000	8,606,000	9,356,000	9,155,000	8,960,000	8,534,000	8,228,000	8,243,000	6,655,000	5,210,000	5,544,000
gain on sale of nonfinancial assets			0	0	0	-10,000,000					0	0	0	-108,000,000					0	0	0	-59,495,000
impairment of assets	0	2,967,000
deferred income taxes	33,342,000	28,429,000	42,387,000	12,172,000	1,252,000	285,000	-24,844,000	-15,029,000	1,252,000	-6,360,000	-51,344,000	-4,198,000	-1,345,000	4,800,000	-3,588,000	-13,224,000	-2,131,000	3,335,000	-34,708,000	-848,335,000	-16,467,000	10,603,000	-22,980,000	-49,697,000	-9,379,000	-704,000	10,056,000	-9,490,000	689,000	-10,753,000	-2,481,000	-149,000	-7,512,000
unrealized foreign exchange gain	4,720,000	-10,026,000	5,599,000	-2,394,000	-9,154,000	-10,804,000	22,992,000	-2,001,000	840,000	6,615,000	1,788,000	-3,742,000
other	-649,000	-1,267,000	21,389,000	-396,000	-985,000	127,000	-141,000	-585,000	583,000	-222,000	-1,343,000	-682,000	-718,000	700,000	-1,312,000	-941,000	495,000	-871,000	-1,385,000	1,038,000	-267,000	-383,000	-1,661,000	3,585,000	-3,584,000	-19,000															-164,000
changes in operating assets and liabilities:
accounts receivable	-98,534,000	-57,590,000	72,547,000	-74,375,000	-52,695,000	-3,386,000	-58,495,000	13,891,000	-7,035,000	-138,796,000	-28,281,000	38,810,000	-37,749,000	-54,813,000	61,000	48,093,000	-22,874,000	40,294,000	-26,120,000	-24,887,000	23,870,000	-31,898,000	23,951,000	-30,773,000	20,660,000	-51,690,000	6,923,000	-9,682,000	8,224,000	-16,540,000	2,025,000	-451,000	-7,842,000	-1,052,000	4,924,000	-9,066,000	-5,162,000	4,198,000	-11,221,000	-7,057,000	-3,163,000	1,021,000	-4,903,000	-30,277,000	-1,008,000	-67,000	-1,376,000	145,000
inventory	-48,127,000	-24,335,000	-34,271,000	18,150,000	-30,589,000	-16,820,000	-59,110,000	-41,472,000	-42,378,000	-14,098,000	-40,845,000	-25,988,000	-2,556,000	1,125,000	-15,935,000	-25,504,000	12,804,000	-6,425,000	12,159,000	-27,012,000	-25,592,000	-20,706,000	-54,983,000	-19,452,000	-34,854,000	1,735,000	-13,921,000	-6,388,000	-7,870,000	-700,000	-14,490,000	-3,329,000	-17,957,000	-7,963,000	-4,017,000	-1,099,000	-3,221,000	-2,605,000	3,586,000	-3,260,000	-5,069,000	-6,293,000	-7,050,000	4,474,000	-895,000	-837,000	-3,276,000	-2,363,000
other current assets	-8,765,000	-6,327,000	16,161,000	-21,554,000	18,968,000	-17,353,000	9,054,000	-5,959,000	-17,429,000	-36,001,000	16,380,000	3,443,000	-3,990,000	-8,011,000	2,731,000	-7,302,000	-8,453,000	42,784,000	-14,536,000	12,407,000	12,139,000	8,302,000	-13,749,000	-8,270,000	-15,101,000	10,112,000	-10,297,000	4,583,000	4,648,000	6,022,000	8,690,000	-2,889,000	2,593,000	-641,000	-1,638,000	2,925,000	3,658,000	1,964,000	6,074,000	25,719,000	-36,428,000	-1,872,000	-5,297,000	541,000	-2,118,000	228,000	-825,000	-443,000
other assets	-11,881,000	-1,624,000	-41,861,000	-8,959,000	-10,750,000	-12,130,000	-10,337,000	-15,196,000	-5,293,000	-323,000	-31,999,000	2,991,000	7,709,000	1,440,000	-6,186,000	-728,000	-1,296,000	1,617,000	-23,104,000	56,000	-5,158,000	-441,000	-1,783,000	-2,519,000	-6,813,000	2,220,000	1,983,000	78,000	2,829,000	-670,000	-947,000	-1,639,000	-3,178,000	498,000	-1,775,000	-871,000	695,000	-307,000	-1,453,000	-221,000	2,329,000	-665,000	-1,478,000	-143,000	-2,746,000	-903,000	-572,000	-524,000
accounts payable and accrued liabilities	5,766,000	-2,655,000												-78,143,000	22,818,000	53,755,000	11,420,000	-72,304,000	-10,851,000	18,251,000	308,000	-94,733,000	55,342,000	59,318,000	4,499,000	-42,070,000	9,058,000	19,057,000	21,586,000	14,393,000	8,650,000	4,146,000						2,803,000	1,863,000	-4,046,000	6,486,000	-3,495,000	12,123,000	-7,681,000	11,197,000	1,990,000	5,278,000	-6,817,000
other long-term liabilities	3,468,000	2,069,000	4,532,000	3,520,000	3,400,000	3,309,000	9,252,000	7,229,000	2,842,000	4,262,000	10,185,000	-1,676,000	-3,286,000	1,710,000	-3,605,000	-316,000	-1,719,000	2,304,000	-16,096,000	3,287,000	794,000	5,144,000	742,000	-7,893,000	8,805,000	1,474,000	4,191,000	3,351,000	-2,591,000	4,390,000	943,000	450,000	860,000	693,000	-702,000	1,049,000
net cash from operating activities	185,271,000	174,394,000	185,627,000	221,481,000	118,762,000	46,971,000	27,483,000	135,646,000	70,062,000	-73,932,000	6,786,000	158,321,000	56,226,000	-45,431,000	11,180,000	97,060,000	82,784,000	113,512,000	-13,384,000	86,206,000	27,737,000	-15,194,000	57,343,000	70,125,000	-24,338,000	-54,868,000	-11,296,000	-9,492,000	11,986,000	14,214,000	-175,000	8,861,000	-15,782,000	9,057,000	22,221,000	3,250,000	19,466,000	29,075,000	19,171,000	20,020,000	3,967,000	1,885,000	7,193,000	-22,220,000	2,064,000	-9,733,000	-6,700,000	-20,126,000
capex	-17,101,000	-16,768,000	-19,530,000	-18,463,000	-21,327,000	-26,104,000	-28,917,000	-21,735,000	-21,583,000	-24,456,000	-35,688,000	-29,300,000	-27,154,000	-28,817,000	-28,738,000	-18,734,000	-22,599,000	-25,507,000	-31,026,000	-16,570,000	-26,162,000	-40,554,000	-50,785,000	-32,854,000	-32,631,000	-28,756,000	-29,684,000	-13,202,000	-13,895,000	-15,013,000	-8,680,000	-56,388,000	0	-9,372,000	-15,240,000	-14,108,000	0	-26,559,000	-21,884,000	-18,737,000	-11,923,000	-12,113,000	0	-19,889,000	0	-5,648,000	0	-3,235,000
free cash flows	168,170,000	157,626,000	166,097,000	203,018,000	97,435,000	20,867,000	-1,434,000	113,911,000	48,479,000	-98,388,000	-28,902,000	129,021,000	29,072,000	-74,248,000	-17,558,000	78,326,000	60,185,000	88,005,000	-44,410,000	69,636,000	1,575,000	-55,748,000	6,558,000	37,271,000	-56,969,000	-83,624,000	-40,980,000	-22,694,000	-1,909,000	-799,000	-8,855,000	-47,527,000	-15,782,000	-315,000	6,981,000	-10,858,000	19,466,000	2,516,000	-2,713,000	1,283,000	-7,956,000	-10,228,000	7,193,000	-42,109,000	2,064,000	-15,381,000	-6,700,000	-23,361,000
cash flows from investing activities:
purchases of property, plant and equipment	-17,101,000	-16,768,000	-19,530,000	-18,463,000	-21,327,000	-26,104,000	-28,917,000	-21,735,000	-21,583,000	-24,456,000	-35,688,000	-29,300,000	-27,154,000	-28,817,000	-28,738,000	-18,734,000	-22,599,000	-25,507,000	-31,026,000	-16,570,000	-26,162,000	-40,554,000	-50,785,000	-32,854,000	-32,631,000	-28,756,000	-29,684,000	-13,202,000	-13,895,000	-15,013,000	-8,680,000	-56,388,000
maturities and sales of investments	117,934,000	77,804,000	154,582,000	160,787,000	186,116,000	131,533,000	113,186,000	260,614,000	275,945,000	215,118,000	142,751,000	165,646,000	155,780,000	155,818,000	188,937,000	153,171,000	154,304,000	194,637,000	210,610,000	175,113,000	75,410,000	94,701,000	104,533,000	212,201,000	203,583,000	219,894,000	56,018,000	77,526,000	72,378,000	58,412,000	54,897,000	81,455,000	70,622,000	85,057,000	28,627,000	22,055,000	102,250,000	46,359,000
purchases of investments	-113,159,000	-89,274,000	-57,879,000	-156,909,000	-73,797,000	-121,665,000	-141,453,000	-282,994,000	-223,685,000	-220,364,000	-154,427,000	-152,577,000
proceeds from sale of nonfinancial assets			0	0	0	10,000,000					-6,675,000	0	0	110,000,000					0	0	0	67,159,000
purchase of intangible assets			-769,000	-2,713,000	-512,000	-8,000,000	-7,779,000	-1,684,000	-1,147,000	-310,000	-671,000	-7,171,000	-881,000	-1,858,000	-15,621,000	-1,626,000	-3,653,000	-2,747,000	-8,838,000	-3,583,000	-7,323,000	-3,463,000	-10,057,000	-2,553,000
net cash from investing activities	-12,592,000	-28,238,000	76,404,000	-16,157,000	90,480,000	-14,236,000	-64,963,000	-45,799,000	29,530,000	-30,012,000	-54,710,000	-23,402,000	-29,699,000	87,782,000	-55,421,000	-119,847,000	-120,257,000	-70,788,000	11,027,000	106,699,000	-248,751,000	77,404,000	-48,896,000	48,678,000	19,671,000	-50,479,000	-306,416,000	3,313,000	-52,353,000	-20,947,000	-34,914,000	-58,321,000	-13,610,000	-4,005,000	-13,129,000	-70,598,000	-45,521,000	-42,867,000	36,401,000	-27,688,000	-54,698,000	14,751,000	-80,492,000	101,362,000	-68,851,000	91,539,000	-203,288,000	29,604,000
cash flows from financing activities:
proceeds from exercises of awards under equity incentive plans			7,862,000	4,797,000	29,421,000	7,197,000	14,805,000	4,355,000	29,024,000	21,169,000	25,467,000	14,373,000	21,258,000	8,235,000	16,317,000	5,237,000	21,823,000	5,817,000	11,645,000	13,341,000	36,811,000	10,116,000	9,843,000	2,755,000	13,215,000	5,798,000
taxes paid related to net share settlement of equity awards	-12,310,000	-38,779,000	-4,909,000	-5,912,000	-16,791,000	-49,948,000	-3,920,000	-4,537,000	-16,440,000	-51,422,000	-3,587,000	-6,319,000	-11,428,000	-32,949,000	-1,377,000	-5,697,000	-9,634,000	-29,097,000	-1,971,000	-6,022,000	-7,801,000	-28,844,000	-1,729,000	-4,051,000	-6,795,000	-30,105,000
net cash from financing activities	-4,603,000	-38,779,000	2,859,000	-499,125,000	12,612,000	-42,793,000	10,840,000	-788,000	11,963,000	-40,742,000	10,869,000	7,541,000	-11,780,000	-25,280,000	14,396,000	-1,031,000	10,951,000	-24,364,000	-366,155,000	3,256,000	563,688,000	-19,671,000	4,042,000	-1,975,000	-51,760,000	-24,981,000	704,928,000	12,299,000	39,564,000	10,306,000	10,107,000	7,758,000	-10,068,000	6,708,000	-2,276,000	9,140,000	1,448,000	5,521,000	-70,102,000	-653,000	2,414,000	2,372,000	5,518,000	12,505,000	3,306,000	4,908,000	316,666,000	-310,000
effect of exchange rate changes on cash	-3,063,000	-1,416,000	2,504,000	-2,901,000	3,300,000	1,927,000	-3,647,000	1,974,000	2,752,000	229,000	71,000	-747,000	-385,000	1,093,000	-22,000	-572,000	742,000	-205,000	1,995,000	614,000	-406,000	-3,353,000	1,737,000	-1,185,000	-365,000	715,000
net increase in cash and cash equivalents	165,013,000	105,961,000	267,394,000	-296,702,000			-30,287,000	91,033,000	114,307,000	-144,457,000	-36,984,000	141,713,000	14,362,000	18,164,000	-29,867,000	-24,390,000	-25,780,000	18,155,000	-366,517,000	196,775,000	342,268,000	39,186,000	14,226,000				387,216,000	6,120,000	-803,000	3,573,000							-24,607,000	-8,272,000	-14,529,000	-8,321,000	-48,317,000	19,008,000	-67,781,000	91,647,000
cash and cash equivalents:
beginning of period	0	942,842,000	0	0	0	755,127,000	0	0	0	724,531,000	0	0	0	587,276,000	0	0	0	649,158,000	0	0	0	437,446,000	0	0	0	493,982,000	0	0	0	0	0	0		0	0	167,171,000		0	0	222,900,000		0	0	228,343,000		0	0	89,162,000
end of period	165,013,000	1,048,803,000	267,394,000	-296,702,000	225,154,000	746,996,000	-30,287,000	91,033,000	114,307,000	580,074,000	-36,984,000	141,713,000	14,362,000	605,440,000	-29,867,000	-24,390,000	-25,780,000	667,313,000	-366,517,000	196,775,000	342,268,000	476,632,000	14,226,000	115,643,000	-56,792,000	364,369,000	387,216,000	6,120,000	-803,000	3,573,000	-24,982,000	-41,702,000		11,760,000	6,816,000	108,963,000		-8,272,000	-14,529,000	214,579,000		19,008,000	-67,781,000	319,990,000		86,815,000	106,679,000	98,331,000
supplemental cash flow disclosures:
cash paid for interest			3,707,000	1,528,000	3,706,000	1,420,000	3,663,000	1,465,000	3,738,000	1,437,000	3,706,000	1,438,000	3,715,000	1,422,000		1,478,000	3,730,000	1,465,000		1,461,000	2,751,000	1,403,000		1,482,000	2,812,000	1,483,000												2,155,000	3,045,000	2,153,000	3,045,000	2,146,000
cash paid for income taxes	51,997,000	10,388,000	21,181,000	13,204,000	20,583,000	2,301,000	21,625,000	23,504,000	23,819,000	4,364,000	40,947,000	1,604,000	10,505,000	1,316,000	2,622,000	5,372,000	7,161,000	2,998,000	4,622,000	1,395,000	693,000	2,267,000	3,638,000	2,155,000	3,027,000	906,000	1,732,000	1,777,000	991,000	677,000	1,009,000	1,088,000	677,000	1,721,000	929,000	254,000	1,758,000	253,000	406,000	407,000	1,029,000	145,000
supplemental cash flow disclosures for non-cash investing and financing activities:
increase in accounts payable and accrued liabilities related to fixed assets	6,479,000	-1,758,000	-15,187,000	-3,484,000	3,774,000	8,167,000	-7,813,000	-692,000
increase in accounts payable and accrued liabilities related to intangible assets			8,442,000				455,000	8,793,000			966,000	-6,787,000	7,200,000	-637,000	39,000	7,992,000	99,000	1,298,000	2,751,000	-520,000
decrease in accounts payable and accrued liabilities related to intangible assets					16,802,000	-8,512,000				-1,478,000
amortization of premium (accretion of discount) on investments							-2,447,000	-2,248,000	-2,563,000	-1,970,000										137,000
impairment of assets and other non-cash adjustments			0	5,685,000
non-cash changes in the fair value of contingent consideration											-539,000	905,000	-651,000	1,989,000	1,772,000	1,766,000	2,233,000	2,255,000	3,148,000	1,936,000	-580,000	-4,000	-441,000	755,000	-7,369,000	12,260,000
accounts payable and other short-term liabilities			-100,259,000	122,280,000	4,745,000	-59,006,000	12,520,000	81,426,000	6,593,000	-31,686,000	61,416,000	73,947,000
repayments of convertible debt			0
payments of contingent consideration							0	0	0	-9,475,000
principal repayments of financing leases					-18,000	-42,000	-45,000	-606,000	-621,000	-1,014,000	-970,000	-513,000	-556,000	-566,000	-547,000	-551,000	-857,000	-1,084,000	-838,000	-4,033,000	-1,104,000	-943,000
net decrease in cash and cash equivalents						-8,131,000																			-56,792,000	-129,613,000					-24,982,000		-39,460,000	11,760,000	6,816,000	-58,208,000
loss on equity investment								0	0	12,650,000
decrease in accounts payable and accrued liabilities related to fixed assets										-8,430,000	3,758,000			-2,481,000		1,703,000	3,402,000	-12,795,000		9,978,000	-3,332,000	-19,927,000		-2,334,000	35,000	-3,502,000		14,616,000
amortization of premium on investments											-698,000	671,000	1,418,000	1,652,000	1,876,000	1,401,000	1,205,000	673,000
inventory reserves, net of stock-based compensation
investment in convertible note																			0	0
repurchase of common stock																			0	0
proceeds from convertible senior subordinated note offering																			0	-30,000
payment of contingent consideration												0
unrealized foreign exchange (gain) loss														-6,887,000								9,400,000		-15,000	1,218,000	-419,000
purchases of available-for-sale securities														-147,361,000		-252,572,000	-247,401,000	-237,171,000		-48,258,000	-281,580,000	-40,104,000		-142,177,000	-146,477,000	-239,843,000
stock-based compensation expense
purchase of available-for-sale debt securities
cash paid for interest, net of interest capitalized into fixed assets																											-1,079,000	205,000	3,068,000	230,000	3,196,000	336,000	3,402,000	2,151,000	2,702,000	1,822,000
unrealized foreign exchange loss																		3,950,000		6,881,000
inventory write-off, net of stock-based compensation
payment of contingent acquisition consideration																								-1,000
(accretion of discount) amortization of premium on investments																						60,000
gain on sale of intangible assets																							-10,000,000	0
gain on sale of equity investment
proceeds from sale of intangible asset
conversion of convertible debt																											16,269,000	31,512,000
proceeds from sale of intangible assets
supplemental cash flow disclosures for non cash investing and financing activities:
(gain) loss on sale of equity investment
non-cash changes in the fair value of contingent consideration\
business acquisitions, net of cash acquired																											0	0			0	0	0	-18,826,000	0	-14,124,000
proceeds from public offering of common stock																											0	0	0	55,000
gain on the sale of equity investments
non-cash changes in the fair value of contingent acquisition consideration
non-cash changes in the fair value of contingent acquisition consideration payable
payment of contingent acquisition consideration payable																													-4,405,000		0	-1,894,000
depreciation and amortization expense
gain on sale of intangible asset
deposit on purchase of pku rights
stock-based compensation capitalized into inventory																											1,902,000	1,829,000	1,305,000	1,181,000	1,320,000	1,499,000	1,434,000	1,381,000	1,244,000	1,080,000	1,327,000	1,424,000	1,369,000	1,303,000	1,295,000	1,274,000
depreciation capitalized into inventory																											2,795,000	2,830,000	2,591,000	2,469,000	2,509,000	2,065,000	2,480,000	2,045,000	1,543,000	1,466,000	1,173,000	1,920,000	689,000	650,000	714,000	741,000
(gain) loss on the sale of equity investments
impairment of intangible assets																											0	0	0	0
funds held in escrow for the purchase of real property
purchase of available-for-sale securities
proceeds from exercises of stock options and the espp
accrual for inventory purchases related to the acquisition of the merck pku business
unrealized foreign exchange gain on forward contracts																															1,475,000								1,699,000	1,624,000	176,000	-304,000	61,000	-161,000
proceeds from exercises of stock options and the employee stock purchase plan
gain on termination of leases
purchase of available-for-sale investments																											-215,850,000	-61,011,000	-105,351,000	-64,346,000	-131,000	-82,733,000
investment in convertible promissory note
excess tax benefit from stock option exercises																											-398,000	118,000	-377,000	-12,000	-306,000	-81,000	-509,000	-19,000			18,000	0	-127,000	-4,000
purchase of promissory note
proceeds from exercises of stock options and employee stock purchase plan
debt conversion expense																											813,000	1,732,000	0		0
proceeds from convertible senior note offering
purchase of capped call share options
payments for debt conversion																											-813,000	-1,732,000
supplemental cash flow disclosures from investing and financing activities:
gain on termination of lease
unrealized foreign exchange (gain) loss on forward contracts																														-2,506,000			-551,000	-2,194,000	-1,415,000	-60,000	-3,725,000
release of escrow balance for purchase of san rafael corporate center
equity in the loss of biomarin/genzyme llc																											438,000	147,000	253,000	336,000	609,000	608,000	796,000	640,000	864,000	691,000		1,320,000	-94,000	547,000
deferred offering costs reclassified into additional paid-in-capital as a result of conversion of convertible debt																											147,000	303,000
restricted funds held in escrow for the purchase of san rafael corporate center
investments in biomarin/genzyme llc																											-400,000	0	-485,000	0	0	-655,000	-718,000	-1,450,000	0	-1,465,000	-740,000
proceeds from exercises of stock options and espp																											12,094,000	14,293,000
other non-cash movements
investment in biomarin/genzyme llc
proceeds from exercises of stock options
payment on maturity of 2013 convertible note																											0	0
repayment of capital lease obligations																											-79,000	-144,000	-143,000	-142,000	-355,000	-53,000	-77,000	-33,000	-42,000	-43,000	-49,000	-45,000	-43,000	-48,000
loss on conversion of convertible promissory note
restricted funds held in escrow
purchase of intellectual property
increase in asset retirement obligation
unrealized foreign exchange loss on forward contracts																												-295,000
changes in the fair value of contingent acquisition consideration payable																												8,832,000	12,113,000	617,000	595,000	2,234,000	-607,000	3,143,000	799,000	654,000
decrease in accrued liabilities related to fixed assets																														318,000
net gain from sale of investments																															0	0	25,000	0	0	-927,000	0
payment on debt conversion
increase in accrued liabilities related to fixed assets
deferred offering costs reclassified into additional paid-in capital as a result of conversion of convertible debt
common stock transferred into the nonqualified deferred compensation plan
equipment acquired through capital leases																															96,000	-176,000
amortization of discount on investments																														1,337,000	981,000	1,002,000
proceeds from exercise of stock options and employee stock purchase plan																														10,381,000
net payment on debt conversion																															0
change in asset retirement obligation																														49,000
net provided by investing activities
imputed interest on acquisition obligation																																	0	0			0	-282,000	1,782,000	1,077,000	1,083,000	1,089,000	1,098,000	1,108,000	1,117,000	1,128,000	1,136,000	1,146,000
impairment loss on equity investments																																	0	0			0
proceeds from espp and exercise of stock options																																				9,183,000			1,914,000	891,000	3,048,000	3,872,000	7,268,000	14,255,000	5,046,000	6,658,000	2,076,000	1,440,000
repayment of acquisition obligation																																	0	0			0	0	-72,100,000	-1,500,000	-1,500,000	-1,500,000	-1,750,000	-1,750,000	-1,750,000	-1,750,000	-1,750,000	-1,750,000
asset retirement obligation
proceeds from employee stock purchase plan (espp) and exercise of stock options																																11,858,000	13,215,000	6,722,000
cash flows from investing activities
changes in accrued liabilities related to fixed assets																																	2,649,000	-13,396,000	1,313,000	4,477,000	-1,276,000	-19,000	-516,000	1,996,000	7,333,000	-3,725,000
changes in contingent acquisition consideration payable																																		3,143,000	-19,657,000	21,110,000
amortization of discount (premium) on investments																																	947,000	1,005,000	1,303,000	1,198,000	954,000
deferred revenue																																	213,000	0	-158,000	72,000	-63,000	-780,000	809,000	-187,000	-1,136,000	-1,793,000	-1,643,000	-448,000	-1,586,000	-1,750,000	-1,788,000	-1,664,000
distributions from biomarin/genzyme llc																																									0	4,000	0	16,679,000	0	6,200,000	4,900,000	6,000,000
investment in equity securities																																	0	0
payment of contingent acquisition payable																																	-9,631,000	0
beginning of year
end of year
distribution of inventory from the joint venture restructure
equipment acquired through capital lease obligations
accounts payable, accrued liabilities and other current liabilities																																		2,565,000	8,322,000	-6,483,000
purchase of property, plant and equipment																																		-9,372,000	-15,240,000	-14,108,000								-19,889,000		-5,648,000
purchase of investments																																		-59,414,000	-26,516,000	-62,956,000	-106,893,000	-61,287,000
supplemental non-cash investing and financing activities disclosures:
investment in la jolla pharmaceutical company																																					0	0	0	-6,250,000
equity in the (income) loss of biomarin/genzyme llc																																										572,000	587,000	533,000
other liabilities																																					-819,000	384,000	984,000	138,000	-326,000	995,000	148,000	143,000	-771,000	-425,000	798,000	401,000
investment in summit corporation plc
acquisition of huxley pharmaceuticals, inc.
payment to lead therapeutics, inc.
net proceeds from convertible debt offering
conversion of convertible notes																																									157,000	6,000
distribution of inventory resulting from the joint venture restructure																																									0	0
equipment acquired through capital lease																																									90,000	143,000
deferred offering costs reclassified to additional paid in capital as a result of convertible notes																																									5,000	0
common shares transferred to nonqualified deferred compensation plan
advances to biomarin/genzyme llc																																						-91,000			32,000	42,000	75,000	1,764,000	-134,000	-651,000	-488,000	782,000
purchase of property and equipment																																						-26,559,000	-21,884,000	-18,737,000	-11,923,000	-12,113,000						-3,235,000
proceeds from employee stock purchase plan and exercise of stock options
impairment loss on investments																																							0	5,848,000
gain on sale of investments
amortization of discount on short-term investments																																								-643,000	-1,018,000	-1,187,000	-1,443,000	-2,839,000	-3,445,000	-3,638,000	-3,177,000	-2,193,000
maturities and sales of short-term investments																																								110,100,000	160,924,000	155,848,000	189,850,000	254,556,000
purchase of short-term investments																																								-112,801,000	-201,731,000	-124,732,000	-257,643,000	-149,025,000	-251,445,000	-166,883,000	-317,178,000	-103,358,000
equity in the income of biomarin/genzyme llc																																													-9,366,000	-8,446,000	-6,550,000	-6,163,000
impairment loss on investment
decrease in cash balances related to long-term debt
repayment of equipment and facility loans
net proceeds from public offering of common stock
cash flows from operating activities
investment summit corporation plc
settlement of forward contracts																																										2,033,000	-256,000	-959,000
loss on disposals and impairment of property and equipment
loss on disposals and impairments of property and equipment
cash flows from financing activities
effect of foreign currency translation on cash																																													-1,000	101,000	1,000	1,000
decrease in restricted cash
sale of short-term investments																																													192,513,000	258,395,000	112,656,000	130,250,000
settlement of dispute with medicis
proceeds from equipment and facility loans
increase in cash balances related to long-term debt
loss on disposals of property and equipment																																														0	0	9,000
net settlement of foreign currency forward contracts																																														-525,000	-73,000	-53,000
proceeds from convertible debt offering																																														0
net increase in cash																																														86,815,000	106,679,000	9,169,000
stock based compensation																																															4,691,000	3,815,000
equity in the loss (income) of biomarin/genzyme llc
acquired in-process research and development
impairment of acquired intangible assets
gain on disposals and impairments of property and equipment
notes receivable from officer
acquisition of ascent pediatrics
decrease (increase) in restricted cash
sales of short-term investments
purchases of short-term investments
reclassification of amounts (to) from cash balances related to long-term debt
proceeds from convertible debt offering, net of offering costs

We provide you with 20 years of cash flow statements for BioMarin Pharmaceutical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BioMarin Pharmaceutical stock. Explore the full financial landscape of BioMarin Pharmaceutical stock with our expertly curated income statements.

The information provided in this report about BioMarin Pharmaceutical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.